Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AK112 in advanced NSCLC
NCT04900363Phase 2Completed
- Sponsor
- Akeso, Inc.
- Start
- May 2021
- Primary completion
- Jun 2024
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ivonescimab in non-small cell lung cancer (NSCLC), sponsored by Akeso, Inc. Primary endpoints: Objective Response Rate at 2 years, Adverse Events at 2 years and 1 more. Started May 2021; status: completed.
02
Drugs
ivonescimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04900363.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04900363.